{"entity":{"id":"david-planchard","kind":"person","name":"David Planchard","aka":[],"tldr":"Gustave Roussy thoracic oncologist on the IFCT board, widely published on BRAF- and EGFR-targeted therapy in lung cancer.","summary":"David Planchard is a medical oncologist at Gustave Roussy (Villejuif) and a member of the IFCT board. He has led or co-led pivotal trials of targeted agents in oncogene-driven non-small cell lung cancer, including BRAF V600E-mutant disease, and contributes to ESMO clinical practice guidelines for metastatic NSCLC.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.ifct.fr/a-propos-de-l-ifct/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Planchard+D%5BAuthor%5D"}],"tags":["clinician-scientist","lung cancer","targeted therapy"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ifct"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Board member (Conseil d'Administration)","institutionId":"ifct","specialisms":["Thoracic oncology","Lung cancer","Targeted therapy"],"profiles":[{"label":"Society page","url":"https://www.ifct.fr/a-propos-de-l-ifct/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Planchard+D%5BAuthor%5D"}],"papers":[{"title":"Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)30146-2"},{"title":"Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC","journal":"New England Journal of Medicine","year":2023,"doi":"10.1056/nejmoa2306434"},{"title":"Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)00077-2"}]},"route":"/people/david-planchard/","neighbours":{"cancer":[{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"company":[{"id":"ifct","kind":"company","name":"Intergroupe Francophone de Cancérologie Thoracique","route":"/companies/ifct/"}],"paper":[{"id":"paper-flaura2-long-term-safety-lung-cancer-2026","kind":"paper","name":"FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer","route":"/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/"},{"id":"paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023","kind":"paper","name":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","route":"/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/"}]}}